BIRD ROCK BIO
![bird-rock-bio-logo](https://linkstock.net/small-thumbnails/b/v1461312934/plqjt5tgos880xbgdtmn.png)
Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utiliz... ing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators.
BIRD ROCK BIO
Industry:
Biotechnology Life Science Therapeutics
Founded:
2002-01-01
Address:
La Jolla, California, United States
Country:
United States
Website Url:
http://www.birdrockbio.com
Total Employee:
11+
Status:
Active
Contact:
(858)587-4815
Email Addresses:
[email protected]
Total Funding:
77.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Apache Wordpress Plugins
Similar Organizations
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Civitas Therapeutics
Civitas Therapeutics is a biopharmaceutical company that focuses on developing pulmonary delivery therapies.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Current Advisors List
Current Employees Featured
Founder
Investors List
Silicon Valley Bank
Silicon Valley Bank investment in Debt Financing - Bird Rock Bio
M Ventures
M Ventures investment in Series B - Bird Rock Bio
Apposite Capital
Apposite Capital investment in Series B - Bird Rock Bio
SR One
SR One investment in Series B - Bird Rock Bio
Versant Ventures
Versant Ventures investment in Series B - Bird Rock Bio
Aravis Ventures
Aravis Ventures investment in Series B - Bird Rock Bio
5AM Ventures
5AM Ventures investment in Series B - Bird Rock Bio
SR One
SR One investment in Series A - Bird Rock Bio
M Ventures
M Ventures investment in Series A - Bird Rock Bio
Aravis Ventures
Aravis Ventures investment in Series A - Bird Rock Bio
Official Site Inspections
http://www.birdrockbio.com Semrush global rank: 5.87 M Semrush visits lastest month: 1.41 K
- Host name: canescredit.com
- IP address: 208.97.145.221
- Location: Brea United States
- Latitude: 33.9339
- Longitude: -117.8854
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 92821
![](/img/wait.gif)
More informations about "Bird Rock Bio"
Bird Rock Bio - Crunchbase Company Profile & Funding
Bird Rock Bio is a clinical stage biopharmaceutical company focused on developing innovative immuno-inflammatory regulators. Bird Rock Bio may be growing as evidenced by recent strategic developments.See details»
Bird Rock Bio, Inc. | LinkedIn
Backed by leading biotechnology venture investors, our strategy leverages biologic targets with substantial human proof of mechanism for the development of novel, best in class therapeutic...See details»
Bird Rock Bio - VentureRadar
Bird Rock Bio is a clinical-stage biopharmaceutical company focused on developing innovative immuno-inflammatory regulators. We are developing first-in-class, best-in-class therapeutic …See details»
Bird Rock Bio - PitchBook
Mar 22, 2012 · Developer of therapeutic antibodies intended to advance the discovery and development of biologic therapeutics.See details»
Skye Completes $17M Financing and Acquires Novel Phase 2 …
Aug 21, 2023 · Skye raised $17M in new capital and acquired Bird Rock Bio Inc. ("Bird Rock"). With Bird Rock's lead asset, nimacimab, Skye intends to advance two complementary but …See details»
Skye Completes $17M Financing and Acquires Novel …
Aug 21, 2023 · Acquisition of Bird Rock Bio builds Skye's position as a leading endocannabinoid system-focused pharmaceutical company. New capital funds anticipated Phase 2a glaucoma clinical trial; Nimacimab is a first-in-class …See details»
Bird Rock Bio Announces Corporate Name Change …
Dec 14, 2015 · Change reflects evolution from discovery research to global clinical development company focused on developing innovative immuno-inflammatory regulators. Bird Rock Bio, Inc., a clinical stage …See details»
Bird Rock Bio Announces Corporate Name Change from RuiYi, Inc.
Dec 14, 2015 · Bird Rock Bio believes gerilimzumab has the potential to effectively compete in the $35 billion global biologic market for rheumatoid arthritis by not only treating the large number …See details»
Bird Rock Bio - Craft
See insights on Bird Rock Bio including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Bird Rock Bio, Inc. Company Profile | San Diego, CA | Competitors ...
Find company research, competitor information, contact details & financial data for Bird Rock Bio, Inc. of San Diego, CA. Get the latest business insights from Dun & Bradstreet.See details»
Bird Rock Bio | San Diego CA - Facebook
Bird Rock Bio, San Diego, California. 31 likes · 2 were here. Bird Rock Bio is a clinical stage biotech company focused on developing innovative immuno-inflammatory regulators.See details»
Skye Bioscience : Acquisition of Bird Rock Bio builds Skye’s …
Aug 21, 2023 · Acquisition of Bird Rock Bio builds Skye's position as a leading endocannabinoid system-focused pharmaceutical company. •New capital funds anticipated Phase 2a glaucoma …See details»
Bird Rock Bio Announces Successful Completion of Phase 1B …
Oct 17, 2019 · Backed by leading biotechnology venture investors, Bird Rock Bio's strategy leverages biologic targets with substantial human proof of mechanism for the development of …See details»
Skye Completes $17M Financing and Acquires Novel Phase 2
Aug 21, 2023 · Skye raised $17M in new capital and acquired Bird Rock Bio Inc. (“Bird Rock”). With Bird Rock’s lead asset, nimacimab, Skye intends to advance two complementary but …See details»
Bird Rock one step closer to acquisition by J&J | BioPharma Dive
Jan 12, 2017 · Just a week after giving exclusive acquisition rights to Johnson & Johnson, clinical-stage biopharma Bird Rock Bio took the first step to that end, announcing the approval of …See details»
Bird Rock Bio Submits Clinical Trial Authorization for the First in ...
LA JOLLA, Calif., Oct. 27, 2016 /PRNewswire/ -- Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, announced that today it has requested approval for the initiation …See details»
Bird Rock Bio's Gerilimzumab, an Anti-IL-6 Antibody, …
LA JOLLA, Calif., March 16, 2016 /PRNewswire/ -- Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, today announced positive results from two clinical studies …See details»
Bird Rock Bio receives approval to start first in human clinical trial ...
Jan 11, 2017 · * Bird Rock Bio says has received approval for initiation of a two-part phase 1 clinical trial for Namacizumab. * Bird Rock Bio says entered into agreement with GE …See details»
Bird Rock Bio Receives Approval to Start First in Human Clinical …
LA JOLLA, Calif., Jan. 11, 2017 /PRNewswire/ -- Bird Rock Bio, Inc. a clinical stage biopharmaceutical company, announced today that it has received approval for the initiation of …See details»
Bird Rock Bio Files IND Application for Phase 2 Study of …
May 28, 2020 · Bird Rock Bio owns the worldwide rights to nimacimab, with patents issued in the U.S. and other territories, including claims to cannabinoid 1 receptor antibodies with inverse …See details»